Overview
Amyl Therapeutics develops Pan-Amyloid Immunotherapy, described as a groundbreaking approach designed to become a universal treatment for neurodegenerative diseases like Alzheimer's and Parkinson's. The therapy is designed to target toxic amyloid species and act at every stage of disease progression.
Funding & milestones
1 events found for Amyl Therapeutics · 2026
Series AVenture / equity1 sourceUSD 9.08M
Reported amount USD 9,075,000
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Key people
In the news
- Amyl Therapeutics secures €8.25M Series A extension to validate novel neurodegenerative disease platform. https://lnkd.in/efBag4AC
- Les Liégeois d'Amyl Therapeutics bouclent une série A de 8,25M€ avec l'aide de Noshaq en vue de développer sa nouvelle plateforme pour lutter contre les maladies neurodégénératives, dont Alzheimer et Parkinson 💊🧠 Dans la foulée, la société devrait agrandir ses laboratoires installés au LégiaPark. Bravo à Pierre Vandepapelière et à toute son équipe 🔬👨🔬#provocateursdepossibles Lire l'article complet dans 📰 L'Echo : Olivier Gosset 📝 Valentin Bianchi 📷 Hans Lucas : https://lnkd.in/eZubBDce
- We're #hiring a new Laboratory and Analytical Operations Lead in Liège, Walloon Region. Apply today or share this post with your network.
- We're #hiring a new Laboratory and Analytical Operations lead in Liège, Walloon Region. Apply today or share this post with your network.
- Job alert ! Amyl Therapeutics is hiring a Lab and Analytical Operations Lead. Do not hesitate to share !
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.